A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer.

ABSTRACT:

Background

Accurate evaluation of the response to neoadjuvant chemotherapy (NAC) provides important information about systemic therapies for breast cancer, which implies pharmacological response, prognosis, and guide further therapy. Gene profiles overcome the shortcomings of the relatively limited detection indicators of the classical pathological evaluation criteria and the subjectivity of observation, but are complicated and expensive. Therefore, it is essential to develop a more accurate, repeatable, and economical evaluation approach for neoadjuvant chemotherapy responses.

Methods

We analyzed the transcriptional profiles of chemo-resistant breast cancer cell lines and tumors of chemo-resistant breast cancer patients in the GSE25066 dataset. We preliminarily screened out

SUBMITTER: Wu J 

PROVIDER: S-EPMC9629837 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature